Assertio Sells Nucynta® Franchise to Collegium for US$375 M

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 2 (Table of Contents)

Published: 14 Feb-2020

DOI: 10.3833/pdr.v2020.i2.2512     ISSN: 1756-7874

Section: Mergers & Acquisitions



Shedding the last of its scandal-plagued opioid business, Assertio has agreed to sell its Nucynta® (tapentadol) franchise to Collegium Pharmaceutical in exchange for US$375 M in cash...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details